HGS-ETR1: A New Antibody for Cancer Treatment
Author Information
Author(s): Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, Carrell J, Boyd E, Yao X T, Zhang L, Zhong L, von Kerczek A, Shepard L, Vaughan T, Edwards B, Dobson C, Salcedo T, Albert V
Primary Institution: Human Genome Sciences Inc.
Hypothesis
Can HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induce cell death in various tumor types?
Conclusion
HGS-ETR1 is a potent antitumor agent that effectively induces apoptosis in multiple tumor types and enhances the efficacy of chemotherapeutic agents.
Supporting Evidence
- HGS-ETR1 showed specific binding to TRAIL-R1 receptor.
- HGS-ETR1 reduced the viability of multiple types of tumour cells in vitro.
- In vivo administration of HGS-ETR1 resulted in rapid tumour regression in xenograft models.
- Combination of HGS-ETR1 with chemotherapeutic agents enhanced antitumour efficacy.
- HGS-ETR1 had a terminal half-life of 6.9–8.7 days in pharmacokinetic studies.
Takeaway
HGS-ETR1 is a special medicine that helps kill cancer cells and works even better when combined with other cancer treatments.
Methodology
The study involved in vitro and in vivo experiments to assess the binding, efficacy, and pharmacokinetics of HGS-ETR1 in various tumor models.
Potential Biases
Potential bias in the selection of tumor models and the interpretation of results.
Limitations
The study primarily focused on specific tumor types and may not generalize to all cancers.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website